Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Jabbour, Elias, Short, Nicholas J., Montalban-Bravo, Guillermo, Huang, Xuelin, Bueso-Ramos, Carlos, Qiao, Wei, Yang, Hui, Zhao, Chong, Kadia, Tapan, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Estrov, Zeev, Cortes, Jorge, Ravandi, Farhad, Alvarado, Yesid, Komrokji, Rami, Sekeres, Mikkael A., Steensma, David P., DeZern, Amy, Roboz, Gail, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2017
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620419/
https://ncbi.nlm.nih.gov/pubmed/28774880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-788497
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak